The ING1 gene encodes p33ING1, a putative tumor suppressor for neuroblastomas and breast cancers, which has been shown to cooperate with p53 in controlling cell proliferation. We have isolated a novel human gene, ING1L, that potentially encodes a PHD-type zinc-finger protein highly homologous to p33ING1. Fluorescence in situ hybridization and radiation-hybrid analyses assigned ING1L to human chromosome 4. Both ING1 and ING1L are expressed in a variety of human tissues, but we found ING1L expression to be significantly more pronounced in tumors from several colon-cancer patients than in normal colon tissues excised at the same surgical sites. Although the significance of this observation with respect to carcinogenesis remains to be established, the data suggest that ING1L might be involved in colon cancers through interference with signal(s) transmitted through p53 and p33ING1.

Aasland R, Gibson TJ, Stewart AF: The PHD finger: implications for chromatin-mediated transcriptional regulation. Trends Biol Sci 20:56–59 (1995).
Baker SJ, Fearon ER, Nigro JM, Hamilton SR, Preisinger AC, Jessup JM, van Tuinen P, Ledbetter DH, Barker DF, Nakamura Y, White R, Vogelstein B: Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 244:217–221 (1989).
Garkavtsev I, Demetrick D, Riabowol K: Cellular localization and chromosome mapping of a novel candidate tumor suppressor gene (ING1). Cytogenet Cell Genet 76:176–178 (1997).
Garkavtsev I, Grigorian I, A Ossovskaya VS, Chernov MV, Chumakov PM, Gudkov AV: The candidate tumor suppressor p33ING1 cooperates with p53 in cell growth control. Nature 391:295–298 (1998).
Garkavtsev I, Kazarov A, Gudkov AV, Riabowol K: Suppression of the novel growth inhibitor p33ING1 promotes neoplastic transformation. Nature Genet 14:415–420 (1996).
Garkavtsev I, Riabowol K: Extension of the replicative life span of human diploid fibroblasts by inhibition of the p33ING1 candidate tumor suppressor. Mol Cell Biol 17:2014–2019 (1997).
Helbing CC, Veillette C, Riabowol K, Johnston RN, Garkavtsev I: A novel candidate tumor suppressor ING1 is involved in the regulation of apoptosis. Cancer Res 57:1255–1258 (1997).
Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 88:323–331 (1997).
Lichter P, Ledbetter SA, Ledbetter DH, Ward DC: Fluorescence in situ hybridization with Alu and L1 polymerase chain reaction probes for rapid characterization of human chromosomes in hybrid cell lines. Proc natl Acad Sci, USA 87:6634–6638 (1990).
Schindler U, Beckmann H, Cashmore AR: HAT3.1 a novel Arabidopsis homeodomain protein containing a conserved cysteine-rich region. Plant J 4:137–150 (1993).
Schwabe JW, Klug A: Zinc mining for protein domains. Nature Struct Biol 1:345–349 (1994).
Takahashi E, Hori T, O’Connell P, Leppert M, White R: R-banding and nonisotopic in situ hybridization: Precise localization of the human type II collagen gene (COL2A1). Hum Genet 86:14–16 (1990).
Takahashi E, Yamauchi M, Tsuji H, Hitomi A, Meuth M, Hori T: Chromosome mapping of the human cytidine-5′-triphosphate (CTPS) gene to band 1p34.3→p34.1. Hum Genet 88:119–121 (1991).
Zeremski M, Horrigan SK, Grigorian IA, Westbrook CA, Gudkov AV: Localization of the candidate tumor suppressor gene ING1 to human chromosome 13q34. Somat Cell Mol Genet 23:233–236 (1997).
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.